Related references
Note: Only part of the references are listed.Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Teriparatide fracture effectiveness in the real world
J. H. Krege et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis
M. M. Bonafede et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Anabolic effects of PTH and the 'anabolic window'
Michael Pazianas
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Cortical Bone: A Challenging Geography
Roger Zebaze et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
Yanfei L. Ma et al.
BONE (2014)
Challenges in longitudinal measurements with HR-pQCT: Evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility
Rafaa Ellouz et al.
BONE (2014)
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis
Erik F. Eriksen et al.
BONE (2014)
Teriparatide Treatment of Severe Osteoporosis Reduces the Risk of Vertebral Fractures Compared with Standard Care in Routine Clinical Practice
Ailsa J. Oswald et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
High-resolution in vivo imaging of bone and joints: a window to microarchitecture
Piet Geusens et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study
C. Senn et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-na⟨ve or on long-term alendronate therapy
B. Hofstetter et al.
OSTEOPOROSIS INTERNATIONAL (2014)
PINP as a biological response marker during teriparatide treatment for osteoporosis
J. H. Krege et al.
OSTEOPOROSIS INTERNATIONAL (2014)
18F-fluoride Positron Emission Tomography Measurements of Regional Bone Formation in Hemodialysis Patients with Suspected Adynamic Bone Disease
Michelle L. Frost et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT
Stinus Hansen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study
Adi Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
S. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
J. H. Krege et al.
BONE (2012)
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
Elizabeth B. Andrews et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
David W. Dempster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The impact of teriparatide adherence and persistence on fracture outcomes
S. Yu et al.
OSTEOPOROSIS INTERNATIONAL (2012)
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges
D. Bauer et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Concise Review: The Periosteum: Tapping into a Reservoir of Clinically Useful Progenitor Cells
Hana Chang et al.
STEM CELLS TRANSLATIONAL MEDICINE (2012)
Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)
A. Fahrleitner-Pammer et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
H. M. Macdonald et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Targeted Regeneration of Bone in the Osteoporotic Human Femur
Kenneth E. S. Poole et al.
PLOS ONE (2011)
Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases
Akimitsu Miyauchi et al.
BONE (2010)
Changes in Cross-Sectional Area of Spinal Canal and Vertebral Body Under 2 Years of Teriparatide Treatment: Results from the EUROFORS Study
R. Schnell et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Quantitative Computed Tomographic Assessment of the Effects of 24 Months of Teriparatide Treatment on 3D Femoral Neck Bone Distribution, Geometry, and Bone Strength: Results From the EUROFORS Study
Jan Borggrefe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
V. Subbiah et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
J. J. Stepan et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial
Kenneth G. Saag et al.
ARTHRITIS AND RHEUMATISM (2009)
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
Sarah J. Glover et al.
BONE (2009)
Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS)
Bente L. Langdahl et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment
Sven Prevrhal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study
Christian Graeff et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate
Harald Dobnig et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study
Helmut Minne et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: The PaTH study
Patrick Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
Barbara M. Obermayer-Pietsch et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies
I. Byrjalsen et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Bone remodeling rate and remodeling balance are not co-regulated in adulthood: Implications for the use of activation frequency as an index of remodeling rate
Juliet E. Compston et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic
Jeffrey S. Stroup et al.
PHARMACOTHERAPY (2007)
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium
Robert Lindsay et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Osteosarcoma and teriparatide?
Kristine D. Harper et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
Yanfei L. Ma et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide
R Lindsay et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography
S Boutroy et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
R Prince et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the fracture prevention trial
EP Paschalis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
JC Gallagher et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Periosteum: biology, regulation, and response to osteoporosis therapies
MR Allen et al.
BONE (2004)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
F Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
The use of biochemical markers of bone turnover in osteoporosis
PD Delmas et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Diagnosis of osteoporosis: Respective roles of biomarkers and bone density measurements: State of the art
PD Delmas
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
